STTK · Shattuck Labs, Inc.

Current Thesis

The narrative leg here is receptor-side TL1A. Every large-pharma bet in the TL1A/IBD space to date — Merck's April 2023 purchase of Prometheus Biosciences, Roche's October 2023 purchase of Telavant — bought a ligand-binding antibody. Shattuck's SL-325 blocks the receptor, DR3, and on 2026-06-08 it became the first DR3-blocking antibody to report human clinical data: 72 healthy volunteers, six single-ascending-dose cohorts from 0.1 mg/kg to 30.0 mg/kg, three multiple-ascending-dose cohorts from 1 mg/kg to 10 mg/kg, complete DR3 receptor occupancy at 0.1 mg/kg and above in all participants, and anti-drug antibodies detected in 3.7% of dosed participants. The shares are up 74.1% over three months, a window that contains that release.

What an investor is buying is not efficacy — there is none yet in patients — but the claim that a validated mechanism can be hit from the receptor side with a cleaner immunogenicity profile than the ligand-side antibodies, funded to 2029, at a market value far below the class comparables. The narrative is maturing: the June dataset is now well known, both published sell-side views arrived in the second half of August (HC Wainwright to $14 on 2026-08-11, Raymond James initiating Strong Buy at $18 on 2026-08-24), and the tape has drifted rather than extended since — the 2026-09-04 close of $6.79 sits 15.8% under the 52-week high of $8.06 with RSI(14) at 39.8.

No current theme cluster carries this name, so nothing in this read leans on a group move. It is a single-name setup whose next company-dated event is a trial start, not a readout.

Bullish and bearish views on Shattuck Labs, Inc.

The model's bull view on Shattuck Labs, Inc. (STTK), in brief: First-in-mechanism human data, 2026-06-08. The bear view: Healthy volunteers are not patients. The 72-subject Phase 1 measured receptor occupancy, TL1A-binding inhibition and immunogenicity. It measured no Crohn's endpoint. Every TL1A-class program that has disappointed has done so in patients, not in Phase 1 pharmacology. The dead… Both cases follow in full.

Bull Case

• First-in-mechanism human data, 2026-06-08. SL-325 reported complete DR3 occupancy at doses of 0.1 mg/kg and higher in all participants, and durable inhibition of TL1A binding for months after a single dose. No other DR3 antagonist has human data.
• Immunogenicity is the differentiating number. Anti-drug antibodies were detected in 3.7% of participants who received SL-325 (2026-06-08 release). Immunogenicity has been the recurring complaint against the ligand-side TL1A antibodies; this is the one biomarker where a receptor-side approach can claim a lead before efficacy exists.
• That guidance excludes any further capital or business-development proceeds.
• Sell-side targets sit well above the tape. Raymond James initiated with a Strong Buy and an $18 target on 2026-08-24; HC Wainwright maintained Buy with a $14 target on 2026-08-11. Both are multiples of the 2026-09-04 close of $6.79.
• A second shot on goal. SL-846, a DR3 × IL-23 receptor bispecific, is the lead next-generation candidate with Phase 1 data expected in 2027 (2026-08-11 release).

Bear Case

• Healthy volunteers are not patients. The 72-subject Phase 1 measured receptor occupancy, TL1A-binding inhibition and immunogenicity. It measured no Crohn's endpoint. Every TL1A-class program that has disappointed has done so in patients, not in Phase 1 pharmacology.
• The dead zone is long. RECEPTIVE-CD1, the Phase 2b in Crohn's disease, was guided on 2026-08-11 to initiate in Q3 2026. An initiation is not a readout; on a standard Phase 2b induction timeline the efficacy answer lands well beyond 2027, and SL-846's own Phase 1 data is guided to 2027.
• Q2 missed and one target came down the same day. Q2 2026 EPS was $(0.12) against a $(0.10) consensus estimate (2026-08-11), and HC Wainwright lowered its target to $14 on that date.
• Burn is scaling into the trial. R&D was $11.7M in Q2 2026 versus $8.7M in Q2 2025; G&A was $4.5M versus $4.4M. Net loss was $15.2M versus $12.5M.
• The share count has done real work. Q2 2026's $15.2M loss printed as $0.12 per share on 129.8M weighted-average shares; Q2 2025's smaller $12.5M loss printed as $0.24 per share. Inferred, not stated by the company: the denominator roughly doubled year over year, and the balance sheet moved from ~$50.5M to $208.3M in the same window. That is capital raised into strength, and it is why the runway extends to 2029.

Setup & Price Structure

Measured, from the adjusted daily series as of 2026-09-04: last close $6.79; 52-week high $8.06; 15.8% below that high; a three-month price change of +74.1%; RSI(14) at 39.8.

The shape is a post-catalyst consolidation, not a trend. The 74.1% three-month advance spans the 2026-06-08 Phase 1 release; the 15.8% give-back and a sub-40 RSI say the move has been distributing since, without a second bid appearing on either the 2026-08-11 print or the 2026-08-24 initiation. That combination — a large realised advance, coverage arriving after the move rather than before it, and momentum cooling into it — is the positioning evidence. Two named brokers now carry the story; the second one arrived at a $18 target eleven days after the first cut its own. New sell-side attention that does not lift the tape is a statement about who is already positioned.

Nothing in the structure supports a fresh breakout read at $6.79. The setup clears on a weekly close back above $8.06 with the Phase 2b start confirmed; it does not clear on a conference appearance.

Catalyst Calendar (next 30 days)

• 2026-09-08 — Wells Fargo 21st Annual Healthcare Conference presentation (CEO Taylor Schreiber, CFO Andrew Neill). Fireside format; the live question is RECEPTIVE-CD1 timing and design.
• 2026-09-09 — Cantor Global Healthcare Conference presentation. Same management, same window.
• ~2026-09-30 (est.) — The Q3 2026 guidance window for initiating RECEPTIVE-CD1 closes. The 2026-08-11 release put the Phase 2b Crohn's trial start inside this quarter; the calendar quarter ends 2026-09-30, which makes this the only hard company-dated test in the window.

Elapsed catalysts

• ~2027 (est.) — SL-846 (DR3 × IL-23R bispecific) Phase 1 data, per the 2026-08-11 release. Outside the window, but it defines how long the news gap runs. (passed 26d ago)

What Would Change Our Mind

The thesis dies quietly, not loudly. Three specific things would do it.

First, the trial start slipping. If 2026-09-30 passes with no RECEPTIVE-CD1 initiation announcement, the Q3 2026 guidance given on 2026-08-11 has failed, and a company whose only near-term proof point is operational execution has missed it. That reframes the 2029 runway from optionality into a long, uncatalysed hold.

Second, price. A weekly close below $5.75 would say the market has stopped treating the 2026-06-08 dataset as a re-rating event and started treating it as noise — at that point the June advance is no longer being digested, it is being reversed, and the $14/$18 published targets are being ignored by the only voters who matter.

Third, the mechanism. A negative patient-level readout from any ligand-side TL1A programme in Crohn's or ulcerative colitis would take the class comparable down with it, and Shattuck has no patient efficacy of its own to defend the receptor-side distinction with.

Conversely, a weekly close above $8.06 with the Phase 2b enrolling would confirm the base and put the narrative back into acceleration.

Correlation Notes

No published theme cluster carries STTK, so the observable correlations are inferred rather than measured here:

• TL1A-class sentiment. Read-through runs both ways from Merck's tulisokibart and Roche's afimkibart programmes. STTK is a receptor-side derivative of a mechanism whose validation was set by pharma M&A in 2023, and class de-rating risk is not diversifiable inside this name.
• Small-cap clinical biotech beta. Pre-revenue, no product sales, $208.3M cash at 2026-06-30 against a $15.2M quarterly loss. The name carries the standard rate and risk-appetite sensitivity of that cohort.
• Single-asset concentration. SL-325 is the story; SL-846 is Phase 1 with data guided to 2027. There is no second programme capable of offsetting an SL-325 setback inside the next twelve months.